#InTheSpotlight | Beyond the hype, what might AI actually mean for healthcare in SA?

With varying degrees of success, artificial intelligence has begun to play the role of research assistant, radiologist, health educator, and even therapist. In this Spotlight special briefing, Jesse Copelyn tries to see past the hype and pin-points the most immediate implications of these new technologies for healthcare in South Africa.

Read More

Competition law has again worked to fight a bad drug patent, but we need other solutions

A Competition Commission probe recently resulted in a patent on an important tuberculosis medicine being dropped in South Africa. Twenty years ago, a similar Competition Commission case resulted in a settlement that helped drive down the prices of several antiretrovirals, thereby helping to set the stage for the country’s HIV treatment programme. Fatima Hassan and Leena Menghaney connect the dots between the two landmark cases and map out what has and has not changed over the last two decades.

Read More

“We were the first ones to do it”: Innovative SA study takes TB testing to people’s homes

Most tuberculosis (TB) tests still require a trip to the clinic. Now, new technology has made it possible to test people at home. This could be a big deal for South Africa, where much TB goes undiagnosed. Tiyese Jeranji unpacks the findings and implications of a recent study into such TB home testing.

Read More

OPEN LETTER | Minister of Health Joe Phaahla, make TB a political priority

In this open letter to Minister of Health Dr Joe Phaahla, TB activists call for the disease to be made a political priority and demand multisectoral departmental accountability. They outline six demands for implementation by the end of this year. The letter was submitted on the final day of the South African TB Conference being held this week in Durban.

Read More

Slow progress after decision to make TB prevention pills more widely available

Besides preventing illness and death, tuberculosis prevention therapy is estimated to be highly cost effective. Yet, uptake of the medication is not what it could be in South Africa. Tiyese Jeranji asks how much has changed since the Department of Health last year decided to make TB prevention therapy much more widely available.

Read More

New TB drug shows promise, but experimental vaccine disappoints

While three new tuberculosis (TB) medicines have been registered in South Africa over the last decade, TB treatment still comes with several side effects and requires taking multiple different medicines, typically for six or more months. The search for better TB medicines got a boost last week with the presentation of promising findings from a study conducted in South Africa on an experimental drug called quabodepistat. Elri Voigt reports on this and other TB studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado.

Read More

1 2 3 16